BioSpace News Archive

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

The author, Thomas Fagan is a retired executive of the Medical Technology Industry and founder of Global Pandemic Consortium which he organized to bring individuals, industry, academia and government together to work towards an effective COVID-19 therapy.

- Company’s goal to initiate clinical trial in patients in 2020 - Innovative therapy candidate uses next generation mesenchymal stem cells (MSCs) derived from a master cell bank of induced pluripotent stem cells (iPSCs)

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been informed by researchers at the U.S. Regional Biocontainment Laboratory (RBL) that continued coronavirus (COVID-19) testing of Brilacidin, the Company’s defensin-mimetic drug candidate, is scheduled to begin the week of May 4. Concurrently, the Company is prioritizing Brilacidin’s clinical developmen

St. Thomas University has launched the Center for Pandemic, Disaster, and Quarantine Research, designed to track the impact of emerging, expanding, and extended pandemics and disasters on all socio-economic aspects of society..

On March 5, 2020, RRS Medical announced the acquisition of Quest Health Information Management Solutions, a St. Louis-based healthcare information management company